What to Expect When Starting Buprenorphine
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Introduction
Buprenorphine is a partial opioid agonist used to treat opioid use disorder (OUD) and chronic pain. For OUD, it is most commonly combined with naloxone (Suboxone) to deter misuse. It reduces cravings and withdrawal symptoms without producing the full euphoric effect of illicit opioids. Starting buprenorphine requires careful induction — beginning too soon after the last opioid use causes precipitated withdrawal.
Week-by-week timeline
The Induction Process
Buprenorphine must be started when you are in mild to moderate withdrawal (typically 12-24 hours after the last short-acting opioid, or 24-72 hours after long-acting opioids). Starting too early causes precipitated withdrawal — a rapid, severe withdrawal syndrome. Your prescriber will guide the induction, often starting with 2-4 mg and increasing doses over the first day until withdrawal is controlled.
Stabilization
Over the first week, the dose is adjusted to eliminate cravings and withdrawal symptoms without causing sedation or euphoria. Common side effects include headache, nausea, constipation, and sweating. The goal is a stable dose where you feel normal — not high, not sick.
Establishing the Maintenance Dose
Most patients stabilize at 8-24 mg/day (Suboxone). The dose is individualized. Once stable, you should experience normalized mood, reduced cravings, and improved daily functioning. Constipation is a persistent side effect — increase fiber and fluids.
Early Recovery
Engage with counseling or support programs alongside medication. Buprenorphine is most effective as part of medication-assisted treatment (MAT) with behavioral support. Sleep may still be disrupted; this normalizes over weeks to months.
Stability and Planning
A stable dose and daily routine are established. Discuss long-term treatment goals with your provider: How long will you take buprenorphine? Indefinite maintenance is appropriate for many patients and significantly reduces overdose risk and relapse rates compared to shorter-term treatment.
When to call your doctor
Contact your healthcare provider if you experience:
- Symptoms of precipitated withdrawal: sudden severe nausea, vomiting, sweating, chills, muscle cramps (call prescriber immediately or go to ER)
- Slow or shallow breathing, unusual drowsiness, or difficulty waking
- Confusion, dizziness, or loss of coordination
- Signs of liver problems: yellowing of skin or eyes, upper-right abdominal pain, dark urine
- Allergic reaction: rash, swelling, breathing difficulty
- Severe constipation with no bowel movement for 3+ days
- Worsening depression or thoughts of self-harm
Tips for getting started
Never start buprenorphine until you are in clear withdrawal — this is critical to avoid precipitated withdrawal. Sublingual film or tablet must dissolve under the tongue completely — do not swallow or chew. Do not use other opioids, benzodiazepines, or alcohol while on buprenorphine — the combination can cause fatal respiratory depression. Carry naloxone (Narcan) and ensure family members know how to use it. Store buprenorphine securely away from children. Engage with counseling and peer support for the best outcomes.
Frequently asked questions
More about Buprenorphine
References
- [Regulatory] FDA Label: Suboxone (buprenorphine/naloxone) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022410s040lbl.pdf Accessed 2026-03-01.
- [Regulatory] SAMHSA: Buprenorphine Practice Guidelines https://store.samhsa.gov/product/tip-63-medications-for-opioid-use-disorder/pep21-02-01-002 Accessed 2026-03-01.
- [Regulatory] NIH MedlinePlus: Buprenorphine Sublingual and Buccal https://medlineplus.gov/druginfo/meds/a605002.html Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: